DE60235416D1 - Diagnostische Marker der akuten koronaren Syndrome und ihre Verwendungen - Google Patents

Diagnostische Marker der akuten koronaren Syndrome und ihre Verwendungen

Info

Publication number
DE60235416D1
DE60235416D1 DE60235416T DE60235416T DE60235416D1 DE 60235416 D1 DE60235416 D1 DE 60235416D1 DE 60235416 T DE60235416 T DE 60235416T DE 60235416 T DE60235416 T DE 60235416T DE 60235416 D1 DE60235416 D1 DE 60235416D1
Authority
DE
Germany
Prior art keywords
immunoassay
subject
cardiac troponin
threshold level
acute coronary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60235416T
Other languages
English (en)
Inventor
Gunars E Valkirs
Jeffrey R Dahlen
Howard Kirchick
Kenneth F Buechler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alere San Diego Inc
Original Assignee
Biosite Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26965308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60235416(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biosite Inc filed Critical Biosite Inc
Application granted granted Critical
Publication of DE60235416D1 publication Critical patent/DE60235416D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
DE60235416T 2001-05-04 2002-05-04 Diagnostische Marker der akuten koronaren Syndrome und ihre Verwendungen Expired - Lifetime DE60235416D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28887101P 2001-05-04 2001-05-04
US31564201P 2001-08-28 2001-08-28

Publications (1)

Publication Number Publication Date
DE60235416D1 true DE60235416D1 (de) 2010-04-01

Family

ID=26965308

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60235416T Expired - Lifetime DE60235416D1 (de) 2001-05-04 2002-05-04 Diagnostische Marker der akuten koronaren Syndrome und ihre Verwendungen
DE60233301T Expired - Lifetime DE60233301D1 (de) 2001-05-04 2002-05-04 Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60233301T Expired - Lifetime DE60233301D1 (de) 2001-05-04 2002-05-04 Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs

Country Status (8)

Country Link
US (2) US7361473B2 (de)
EP (3) EP1666881B1 (de)
JP (3) JP3806694B2 (de)
AT (2) ATE439588T1 (de)
AU (1) AU2002305394A1 (de)
CA (1) CA2414073A1 (de)
DE (2) DE60235416D1 (de)
WO (1) WO2002089657A2 (de)

Families Citing this family (251)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6991907B1 (en) 1995-04-18 2006-01-31 Biosite, Inc. Methods for the assay of troponin I and T and complexes of troponin I and T and selection of antibodies for use in immunoassays
US6627404B1 (en) * 1995-04-18 2003-09-30 Biosite, Inc. Methods for improving the recovery of troponin I and T in membranes, filters and vessels
DE19847690A1 (de) * 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US20030219734A1 (en) * 2001-04-13 2003-11-27 Biosite Incorporated Polypeptides related to natriuretic peptides and methods of their identification and use
US20040176914A1 (en) * 2001-04-13 2004-09-09 Biosite Incorporated Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US7524635B2 (en) * 2003-04-17 2009-04-28 Biosite Incorporated Methods and compositions for measuring natriuretic peptides and uses thereof
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
US20030199000A1 (en) * 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
EP1419388B1 (de) * 2001-08-20 2009-10-07 Biosite Incorporated Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon
US20040219509A1 (en) * 2001-08-20 2004-11-04 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20040209307A1 (en) * 2001-08-20 2004-10-21 Biosite Incorporated Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7608406B2 (en) 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US6461828B1 (en) 2001-09-04 2002-10-08 Syn X Pharma Conjunctive analysis of biological marker expression for diagnosing organ failure
HUE039881T2 (hu) 2002-05-09 2019-02-28 Brigham & Womens Hospital Inc 1L1RL-1, mint egy kardiovaszkuláris betegség-marker
MXPA03004105A (es) 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
EP2386862A1 (de) * 2002-10-09 2011-11-16 DMI Biosciences, Inc. Verfahren und Kits zur Diagnose von Blinddarmentzündung
DE60331584D1 (de) * 2002-11-26 2010-04-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
GB0229747D0 (en) * 2002-12-20 2003-01-29 Axis Shield Asa Assay
WO2004059293A2 (en) * 2002-12-24 2004-07-15 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
ATE437371T1 (de) * 2003-03-27 2009-08-15 Childrens Hosp Medical Center Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
JP2006527190A (ja) * 2003-04-17 2006-11-30 サイファージェン バイオシステムズ インコーポレイテッド ナトリウム利尿ペプチドに関連したポリペプチド、並びにこれらの同定および使用法
US20060177870A1 (en) * 2003-04-28 2006-08-10 Ciphergen Biosystems, Inc Immunoassays
WO2004105575A2 (en) * 2003-05-29 2004-12-09 Trustee Of Darmouth College A method for detecting cardiac ischemia via changes in b-natriuretic peptide levels
WO2005033327A2 (en) * 2003-09-29 2005-04-14 Biosite Incorporated Methods and compositions for the diagnosis of sepsis
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
DE10351238A1 (de) * 2003-11-03 2005-06-02 Roche Diagnostics Gmbh Diagnosestellung von akuten myokardialen, ischämischen Erkrankungen durch Kombination von Markern
WO2005047882A2 (en) * 2003-11-07 2005-05-26 Princeton Biochemicals, Inc. Multi-dimensional electrophoresis apparatus
EP1530047A1 (de) * 2003-11-07 2005-05-11 Roche Diagnostics GmbH Proximale Markermoleküle der Arterienthrombose und der Entzündung zur Risikostratifizierung einer koronaren Herzkrankheit
US20050196817A1 (en) * 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
US20080175191A1 (en) * 2004-02-23 2008-07-24 Siemens Aktiengesellschaft Method, Intermediate Station and Central Control Unit For the Packet-Switched Data Transmission in a Self-Organizing Radio Network
US20050244892A1 (en) * 2004-02-27 2005-11-03 Lazar Mitchell A Resistin as a marker and therapeutic target for cardiovascular disease
DE602005018914D1 (de) * 2004-04-15 2010-03-04 Athera Biotechnologies Ab Annexin zur prävention von der ruptur des plaques
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
DE102004028303A1 (de) 2004-06-11 2005-12-29 Roche Diagnostics Gmbh Verfahren und Vorrichtung zum Nachweis von Analyten
WO2005124364A1 (en) 2004-06-15 2005-12-29 F. Hoffmann-La Roche Ag The use of cardiac hormones for diagnosing the risk of suffering from a cardiovascular complication as a consequence of cardiotoxic medication
EP1615035B1 (de) * 2004-07-07 2007-06-06 F.Hoffmann-La Roche Ag Kombinationen von Markern zum Nachweis von typ 1 und 2 Diabetes
ES2703434T3 (es) * 2004-12-20 2019-03-08 Antibodyshop As Determinación de lipocalina asociada a gelatinasa de neutrófilos (NGAL) como marcador diagnóstico para trastornos renales
US20080050832A1 (en) * 2004-12-23 2008-02-28 Buechler Kenneth F Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20080207505A1 (en) * 2005-01-12 2008-08-28 James Kenneth D Bna Conjugates and Methods of Use
US7432107B2 (en) 2005-01-24 2008-10-07 Roche Diagnostics Operations, Inc. Cardiac hormones for assessing cardiovascular risk
ES2316044T3 (es) * 2005-01-24 2009-04-01 F. Hoffmann-La Roche Ag El uso de hormonas cardiacas para evaluar un riesgo cardiovascular con respecto a la administracion de farmacos antiinflamatorios.
EP1691200A1 (de) * 2005-02-14 2006-08-16 F. Hoffmann-La Roche Ag Verwendung des BNP-Art und ANP-Art Peptiden für das Festsetzen der Gefahren von Herzgefäß- Komplikationen als Folge der Volumenüberlastung
DE102005003687A1 (de) * 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
ATE509270T1 (de) 2005-02-21 2011-05-15 Univ Saga Aus blutplättchen gewonnene mikropartikel als neue diagnosemarker für eine herz-kreislauf- erkrankung
US20060199280A1 (en) * 2005-03-03 2006-09-07 David Bar-Or Quantification of proteins
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20060240444A1 (en) * 2005-04-21 2006-10-26 Peiguo Chu Detection methods
US7300631B2 (en) * 2005-05-02 2007-11-27 Bioscale, Inc. Method and apparatus for detection of analyte using a flexural plate wave device and magnetic particles
CN100422742C (zh) * 2005-05-16 2008-10-01 艾博（武汉）生物技术有限公司 急性心肌梗死早期诊断三合一检测试剂板
CN101268369A (zh) * 2005-06-29 2008-09-17 儒勒斯贝斯特医药有限公司 诊断急性冠状动脉综合症的方法和试剂盒
ES2288358B1 (es) * 2005-07-01 2008-11-16 Proyecto De Biomedicina Cima, S.L. Marcadores de fibrosis.
JP4850001B2 (ja) * 2005-09-05 2012-01-11 プリマハム株式会社 新規ストレスバイオマーカー及びその用途
IL172297A (en) 2005-10-03 2016-03-31 Compugen Ltd Soluble vegfr-1 variants for the diagnosis of preeclampsia
JP2009510478A (ja) * 2005-10-03 2009-03-12 バイオサイト インコーポレイテッド 全身性炎症反応症候群の診断および／または予後診断のための方法および組成物
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
US7399598B2 (en) * 2005-10-14 2008-07-15 Taipei Medical University Diagnosis method of endometriosis by detecting biochemical markers and usage of these biochemical markers
US20110076255A1 (en) * 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
JP2007131548A (ja) * 2005-11-08 2007-05-31 Hirosaki Univ プロテオグリカンの新規医薬用途
EP2431746A1 (de) 2005-11-17 2012-03-21 Biogen Idec MA Inc. Thrombozytenaggregationsprüfungen
US9829494B2 (en) * 2005-12-01 2017-11-28 Adrenomed Ag Methods of treatment using ADM antibodies
US8906857B2 (en) * 2005-12-01 2014-12-09 B.R.A.H.M.S. Gmbh Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
GB0601058D0 (en) * 2006-01-19 2006-03-01 Univ Southampton Mast Cell Carboxypeptidase As A Marker For Anaphylaxis And Mastocytosis
US20070172888A1 (en) * 2006-01-25 2007-07-26 Klaus Hallermayer Measuring troponin antibodies to assess cardiovascular risk
WO2011050103A1 (en) 2009-10-21 2011-04-28 The Scripps Research Institute Method of using non-rare cells to detect rare cells
EP2005168A4 (de) * 2006-03-09 2009-05-20 Biosite Inc Verfahren und zusammensetzung zur diagnose von krankheiten der aorta
ATE470862T1 (de) * 2006-03-24 2010-06-15 Hoffmann La Roche Vorrichtung und verfahren zur unterscheidung zwischen akuter und chronischer myokardial- nekrose bei symptomatischen patienten
AU2014200749B2 (en) * 2006-04-04 2016-04-14 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
ES2550004T3 (es) 2006-04-04 2015-11-03 Singulex, Inc. Sistema de alta sensibilidad y métodos de análisis de la troponina
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
JP6325022B2 (ja) * 2006-04-04 2018-05-16 シングレックス，インコーポレイテッド トロポニンの分析のための高感度のシステムおよび方法
EP1845379A1 (de) 2006-04-13 2007-10-17 F. Hoffmann-La Roche AG Mittel und Verfahren zur Differenzierung kardialer und pulmonaler Ursachen von Atemnot
EP2241888B1 (de) 2006-04-24 2011-10-05 Critical Care Diagnostics, Inc. Vorhersage von Letalität und Detektion von schweren Erkrankungen
US8129135B2 (en) * 2006-04-24 2012-03-06 Medizinische Universität Wien Method for diagnosing cardiovascular diseases
JP5377289B2 (ja) * 2006-05-01 2013-12-25 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心血管疾患の診断方法
SI2019965T1 (sl) * 2006-05-02 2015-10-30 Critical Care Diagnostics, Inc. Diferencialna diagnoza med pljučno boleznijo in boleznijo srca in ožilja
US20080118924A1 (en) * 2006-05-26 2008-05-22 Buechler Kenneth F Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases
US20090197280A1 (en) 2006-05-30 2009-08-06 Kristian Bangert Methods and Devices for Rapid Assessment of Severity of Injury
US7935498B2 (en) * 2006-07-07 2011-05-03 Siemens Healthcare Diagnostics Inc. Methods for identifying patients with increased risk of an adverse cardiovascular event
EP1882945A1 (de) 2006-07-28 2008-01-30 F.Hoffmann-La Roche Ag Vorrichtungen und Verfahren zur Differentierung zwischen herz- und lungenbedingten Ursachen für akute Atemnot
ATE511656T1 (de) 2006-08-04 2011-06-15 Hannover Med Hochschule Verfahren zur risikobewertung von herzeingriffen auf gdf-15-basis
EP2064553B2 (de) * 2006-08-07 2023-06-07 Antibodyshop A/S Diagnostischer test zum ausschliessen einer signifikanten nierenverletzung
EP1890153A1 (de) * 2006-08-16 2008-02-20 F. Hoffman-la Roche AG Herztroponin als Indikator für fortgeschrittene Koronararterienerkrankung
US20080050749A1 (en) * 2006-08-17 2008-02-28 Ildiko Amann-Zalan Use of bnp-type peptides for the stratification of therapy with erythropoietic stimulating agents
US8158374B1 (en) 2006-09-05 2012-04-17 Ridge Diagnostics, Inc. Quantitative diagnostic methods using multiple parameters
EP1901072B1 (de) 2006-09-15 2009-11-25 F. Hoffman-la Roche AG Biochemische Marker für akute Lungenembolie
EP1901073A1 (de) 2006-09-18 2008-03-19 Roche Diagnostics GmbH Natriuretische Peptide zur Diagnose von Herzkomplikationen infolge von Koronarkatheterisierung
ATE476665T1 (de) * 2006-09-20 2010-08-15 Hoffmann La Roche Natriurethische peptide und plazenta- wachstumfaktor/löslicher vegf-rezeptor unterscheiden zwischen mit der plazenta verbundener herzdysfunktion und mit herzerkrankung verbundener herzdysfunktion
ES2652027T3 (es) 2006-10-26 2018-01-31 B.R.A.H.M.S. Gmbh Estratificación de riesgo del síndrome coronario agudo por medio de fragmentos / péptidos parciales de la provasopresina, en particular copeptina o neurofisina II
WO2008060607A2 (en) * 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
EP2095106B1 (de) * 2006-11-14 2013-03-20 Alere San Diego, Inc. Verfahren und zusammensetzungen zur diagnose und prognose von nierenarterienstenose
EP1925943A1 (de) 2006-11-21 2008-05-28 F. Hoffman-la Roche AG Vorrichtungen und Verfahren zur Optimierung von diagnostischen and therapeutischen Ansätzen für chronische Arterienerkrankungen basierend auf dem Nachweis von Troponin T und NT-proBNP.
US9625453B2 (en) * 2006-11-28 2017-04-18 Pictor Limited Assay membrane and method of use thereof
WO2008089994A1 (en) * 2007-01-25 2008-07-31 Roche Diagnostics Gmbh Use of igfbp-7 in the assessment of heart failure
DK2614832T3 (da) 2007-02-12 2016-10-31 A1M Pharma Ab Diagnose og behandling af præeklampsi
ES2440740T3 (es) * 2007-03-08 2014-01-30 F. Hoffmann-La Roche Ag Utilización de SLIM-1 en la evaluación de la insuficiencia cardiaca
GB0705223D0 (en) * 2007-03-19 2007-04-25 Univ Sussex Method, apparatus and computer program for analysing medical image data
CN101680903A (zh) * 2007-03-21 2010-03-24 比奥波托诊断股份公司 肾损伤的诊断试验
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
JP5214723B2 (ja) 2007-04-30 2013-06-19 ナノゲン・インコーポレイテッド 多分析物アッセイ
DE102007022367A1 (de) * 2007-05-07 2008-11-20 B.R.A.H.M.S Ag Verfahren zur Bestimmung von aminoterminalen pro-ANP bei übergewichtigen Patienten
EP2150811B1 (de) * 2007-05-08 2013-01-16 Abbott Laboratories Test für menschliches natriuretisches typ-b-peptid mit verminderter kreuzreaktivität mit anderen peptidformen
EP1998178A1 (de) * 2007-05-29 2008-12-03 F. Hoffman-la Roche AG H-FABP als Prädiktor für Herzinfarkt
EP2167965B1 (de) * 2007-06-22 2013-04-10 B.R.A.H.M.S GmbH Verfahren zur detektion von analyten
EP2293078B1 (de) 2007-08-03 2011-11-09 B.R.A.H.M.S GmbH Verfahren zur Diagnose bakterieller Infektionen
EP2031397A1 (de) 2007-08-30 2009-03-04 F. Hoffmann-La Roche AG Surfactantproteine B und D bei der Unterscheidung der Ursachen für Atemnot
EP2210111A1 (de) 2007-10-10 2010-07-28 Roche Diagnostics GmbH Natriuretisches peptid/troponin-verhältnis zur beurteilung bereits vorhandener myokard-fehlfunktion bei patienten mit akutem koronarsyndrom
JP6039879B2 (ja) * 2007-11-05 2016-12-07 ノルディック・ビオサイエンス・エー／エスＮｏｒｄｉｃ Ｂｉｏｓｃｉｅｎｃｅ Ａ／Ｓ Ｃｖｄリスク評価のための生化学マーカー
ES2475990T5 (es) * 2007-11-15 2017-07-06 Bioporto Diagnostics A/S Uso diagnóstico de formas moleculares individuales de un biomarcador
EP2231186A4 (de) 2007-12-17 2012-08-08 Dyax Corp Zusammensetzungen und verfahren zur behandlung von osteolytischen erkrankungen mit mmp-14-bindungsproteinen
EP2262840A4 (de) 2008-03-03 2012-08-08 Dyax Corp Metalloproteinase-9- und metalloproteinase-2-bindende proteine
JP2011517662A (ja) * 2008-03-03 2011-06-16 ダイアックス コーポレーション メタロプロテアーゼ９結合タンパク質
US20100100333A1 (en) * 2008-10-15 2010-04-22 Ridge Diagnostics, Inc. Human biomarker hypermapping for depressive disorders
CN102016552A (zh) * 2008-03-05 2011-04-13 神谷来克斯公司 用于分子的高灵敏性检测的方法和组合物
US7927880B2 (en) 2008-05-21 2011-04-19 Mohan Rajapurkar Methods and kit for early detection of acute coronary syndrome and prediction of adverse cardiac events
EP2250500B8 (de) * 2008-03-05 2013-08-28 Mohan Rajapurkar Vorhersage von schweren unerwünschten kardialen ereignissen
EP2103943A1 (de) 2008-03-20 2009-09-23 F. Hoffman-la Roche AG GDF-15 zur Beurteilung eines kardiovaskulären Risikos hinsichtlich Verabreichung von Entzündungshemmern
PT2827152T (pt) 2008-04-18 2016-09-13 Critical Care Diagnostics Inc Previsão do risco de eventos cardíacos adversos maiores
EP2294424A1 (de) 2008-05-21 2011-03-16 F. Hoffmann-La Roche AG L-fabp, natriuretische peptide und herztroponin bei individuen, die eine herztherapie benötigen
EP2294425B1 (de) 2008-05-23 2013-05-22 The Johns Hopkins University Biomarker für myokardischämie
EP2133696A1 (de) 2008-06-10 2009-12-16 Eberhardt Spanuth Sehr geringe Konzentrationen von Troponin I oder T zur Beurteilung eines kardiovaskulären Risikos hinsichtlich der Verabreichung von Entzündungshemmern
JP2011523072A (ja) * 2008-06-13 2011-08-04 エフ．ホフマン−ラ ロシュ アーゲー １型糖尿病を有する患者の合併症の評価
EP2148203A1 (de) * 2008-07-23 2010-01-27 BRAHMS Aktiengesellschaft Azurophili-Granulat-Proteasen als Marker bei Herzkrankheiten
EP2324358A1 (de) * 2008-07-23 2011-05-25 F. Hoffmann-La Roche AG Überwachung einer antiangiogenesetherapie
ES2644723T3 (es) 2008-07-23 2017-11-30 F. Hoffmann-La Roche Ag Identificación de sujetos susceptibles de tratamiento antiangiogénico
CA2732201A1 (en) 2008-08-13 2010-02-18 F. Hoffmann-La Roche Ag D-dimer, troponin, nt-probnp for pulmonary embolism
WO2010023749A1 (ja) * 2008-08-28 2010-03-04 株式会社 島津製作所 血液試料を用いて心筋虚血状態を評価する方法
US20120083421A1 (en) * 2008-10-16 2012-04-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan)
ES2431358T3 (es) * 2008-11-11 2013-11-26 B.R.A.H.M.S Gmbh Pronóstico y evaluación del riesgo en pacientes que padecen insuficiencia cardíaca mediante la determinación de la concentración de ADM
JP5767973B2 (ja) * 2008-11-18 2015-08-26 リッジ ダイアグノスティックス，インコーポレイテッド 大うつ病性障害のためのメタボリック症候群バイオマーカーおよびｈｐａ軸バイオマーカー
US8457724B2 (en) * 2008-12-11 2013-06-04 Siemens Medical Solutions Usa, Inc. System for heart performance characterization and abnormality detection
CN102341705B (zh) * 2009-03-05 2015-08-19 味之素株式会社 克罗恩氏病诊断试剂
KR101894597B1 (ko) * 2009-03-11 2018-10-04 오거렉스 라이프 사이언시스 코포레이션 관절염 상태를 특성화하는 조성물 및 방법
US20110213219A1 (en) * 2010-01-26 2011-09-01 Ridge Diagnostics, Inc. Multiple Biomarker Panels to Stratify Disease Severity and Monitor Treatment of Depression
JP2012523009A (ja) * 2009-04-06 2012-09-27 リッジ ダイアグノスティックス，インコーポレイテッド 精神神経疾患の治療をモニタリングするためのバイオマーカー
AU2010242163B2 (en) 2009-04-29 2014-10-16 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure
US20120303083A1 (en) * 2009-05-26 2012-11-29 The Johns Hopkins University Novel desmin phosphorylation sites useful in diagnosis and intervention of cardiac disease
AU2010259022B2 (en) * 2009-06-08 2016-05-12 Singulex, Inc. Highly sensitive biomarker panels
US20120164662A1 (en) * 2009-06-10 2012-06-28 HARA Masanori Test method on renal diseases
US8889625B2 (en) * 2009-07-10 2014-11-18 Northwestern University Cardioprotective role of hepatic cells and hepatocyte secretory factors in myocardial ischemia
MX339184B (es) 2009-09-17 2016-05-16 Hoffmann La Roche Panel multimarcador para hipertrofia ventricular izquierda.
WO2011057251A2 (en) 2009-11-09 2011-05-12 The Brigham And Women's Hospital, Inc. Treatment of heart disease
WO2011057249A2 (en) 2009-11-09 2011-05-12 The Brigham And Women's Hospital, Inc. Treatment of heart disease
US9274126B2 (en) * 2009-11-13 2016-03-01 Bg Medicine, Inc. Risk factors and prediction of myocardial infarction
ES2665621T3 (es) * 2009-11-27 2018-04-26 Baker Idi Heart And Diabetes Institute Holdings Ltd Biomarcadores lipidómicos para la enfermedad cardiaca estable e inestable
EP2336784B1 (de) 2009-12-18 2017-08-16 Roche Diagnostics GmbH GDF-15 und/oder Troponin T zur Prognose von Nierenausfällen bei Herzinsuffizienzpatienten
EP2533653B1 (de) 2010-02-12 2015-01-28 Synlab Medizinisches Versorgungszentrum Heidelberg GmbH Homoarginin als Biomarker des Sterberisikos
CN102906568B (zh) * 2010-03-24 2014-11-12 普利鲁米那诊断公司 作为先兆子痫早期阶段标志物的HbF和A1M
WO2011140484A1 (en) 2010-05-06 2011-11-10 Singulex, Inc Methods for diagnosing, staging, predicting risk for developing and identifying treatment responders for rheumatoid arthritis
EP2388594A1 (de) 2010-05-17 2011-11-23 Roche Diagnostics GmbH Mittel auf GDF-15-Basis sowie Verfahren zur Überlebens- und Genesungsvorhersage bei akuter Entzündung
WO2011149962A1 (en) 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
US8602996B2 (en) 2010-06-01 2013-12-10 Cardiac Pacemakers, Inc. Integrating device-based sensors and bedside biomarker assays to detect worsening heart failure
PL2596119T3 (pl) * 2010-07-23 2021-12-06 Astellas Institute For Regenerative Medicine Sposoby wykrywania rzadkich subpopulacji komórek i kompozycje wysoko oczyszczonych komórek
CN101942416B (zh) * 2010-07-23 2012-03-28 中国医学科学院放射医学研究所 抗人心肌肌钙蛋白i特异性单克隆抗体及其制备方法
US10161928B2 (en) * 2010-07-26 2018-12-25 Wellmetris, Llc Wellness panel
WO2012020045A1 (en) 2010-08-10 2012-02-16 Roche Diagnostics Gmbh Method for selecting patients with stable coronary artery disease for pci or medical treatment
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
EP2367006A1 (de) 2010-08-24 2011-09-21 Roche Diagnostics GmbH Mittel und Verfahren auf PLGF-Basis zur Diagnose kardialer Ursachen bei akuten Entzündungen
CN108387744A (zh) 2010-08-26 2018-08-10 弗·哈夫曼-拉罗切有限公司 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途
EP2439535A1 (de) 2010-10-07 2012-04-11 F. Hoffmann-La Roche AG Diagnose von Herzerkrankungen im Zusammenhang mit Diabetes und GDF-15 und Troponin als Prädiktor für die Entwicklung von Diabetes mellitus Typ 2
EP2447720A1 (de) 2010-10-26 2012-05-02 Roche Diagnostics GmbH sFlt1 und Lungenkomplikationen
US8868168B2 (en) 2010-11-11 2014-10-21 Siemens Medical Solutions Usa, Inc. System for cardiac condition characterization using electrophysiological signal data
US8818494B2 (en) 2010-11-29 2014-08-26 Siemens Medical Solutions Usa, Inc. System for ventricular function abnormality detection and characterization
EP2383579A1 (de) 2010-12-17 2011-11-02 F. Hoffmann-La Roche AG sFlt-1, Kardiotroponine und natriuretische Peptide beim Nachweis einer Therapie mit HER-2-Inhibitoren
CN107831318B (zh) * 2011-01-20 2021-06-18 西瑞斯实验室有限公司 检测谷蛋白敏感性和其区分于乳糜泻的方法和装置
GB2490652A (en) * 2011-04-18 2012-11-14 Microtest Matrices Ltd Methods of quantifying antibodies, especially IgE antibodies in a sample
US8754044B2 (en) 2011-05-03 2014-06-17 Northwestern University Neuroprotection by hepatic cells and hepatocyte secretory factors
US8684942B2 (en) 2011-05-25 2014-04-01 Siemens Medical Solutions Usa, Inc. System for cardiac impairment detection based on signal regularity
EP2385373A1 (de) 2011-07-01 2011-11-09 F. Hoffmann-La Roche AG Natriuretische Peptide bei der Schwangerschaft
US20120258477A1 (en) * 2011-07-25 2012-10-11 Northwestern University Fecal neopterin concentration measurement as an indicator of disease activity in inflammatory bowel disease
EP2581040A1 (de) 2011-10-10 2013-04-17 Roche Diagnostics GmbH TNT-basiertes Herzhypertrophierisiko im Zusammenhang mit physiologischem Training und Führung in Athleten
ES2824110T3 (es) 2011-10-17 2021-05-11 Hoffmann La Roche Troponina como marcador de fibrilación auricular intermitente
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
US9402900B2 (en) 2011-11-16 2016-08-02 Adrenomed Ag Methods of modulating adrenomedullin by administering an anti-adrenomedullin (ADM) antibody
HUE032648T2 (en) 2011-11-16 2017-10-30 Sphingotec Gmbh Adrenomedullin assays and procedures for determining the concentration of mature adrenomedullin
HUE042477T2 (hu) 2011-11-16 2019-07-29 Adrenomed Ag Anti-adrenomedullin (ADM) ellenanyag vagy anti-ADM ellenanyag-fragmens vagy anti-ADM nem-Ig váz krónikus vagy akut betegségben szenvedõ páciens folyadékegyensúlyának szabályozására
RS58880B1 (sr) 2011-11-16 2019-08-30 Adrenomed Ag Antitelo na adrenomedulln (adm) ili fragment antitela na adm ili struktura antitela na adm bez ig za sprečavanje ili smanjenje disfunkcije organa ili insuficijencije organa u pacijentu koji ima hroničnu ili akutnu bolest ili akutno stanje
CA2856461C (en) 2011-12-01 2020-08-18 F. Hoffmann-La Roche Ag Nt-proanp and nt-probnp for the diagnosis of stroke
CN103163295B (zh) * 2011-12-08 2015-11-18 吴宗贵 一种用于急性冠脉综合征的液相芯片试剂盒以其制备方法
BR112014014456A2 (pt) * 2011-12-15 2018-09-25 Pronota Nv biomarcadores e parâmetros para distúrbios hipertensivos da gravidez
JP5814800B2 (ja) * 2011-12-28 2015-11-17 株式会社Ｌｓｉメディエンス 神経変性疾患の検出方法
EP2620773B1 (de) 2012-01-26 2015-03-18 Roche Diagniostics GmbH Verfahren zur Differenzierung eines Vor- und Rückwärtsherzversagens
US20130196870A1 (en) * 2012-01-31 2013-08-01 Medical University Of South Carolina Systems and methods using biomarker panel data
US10502747B2 (en) 2012-01-31 2019-12-10 Cardiac Pacemakers, Inc. Systems and methods using biomarker panel data
EP2650684A1 (de) 2012-04-10 2013-10-16 Roche Diagniostics GmbH Diagnose auf Pro-SP-B und NT-proBNP bei Patienten mit Lungenentzündung
US8903480B2 (en) 2012-04-11 2014-12-02 Siemens Medical Solutions Usa, Inc. System for cardiac condition detection using heart waveform area associated analysis
CN104428674A (zh) * 2012-04-24 2015-03-18 思研（Sri）国际顾问与咨询公司 前列腺癌和sar-cov的人血清生物标记物
EP2615459A1 (de) 2012-04-27 2013-07-17 Roche Diagniostics GmbH Verfahren zur Diagnose von Distalbronchoalveolargewebeschäden in Asthma durch Erkennen von proSP-B
WO2013181127A1 (en) * 2012-05-30 2013-12-05 Clarient Diagnostic Services, Inc. Multiplexed assay method for lung cancer classification
WO2013183725A1 (ja) * 2012-06-06 2013-12-12 国立大学法人九州大学 非ヒトモデル動物、非ヒトモデル動物の作製方法及び抗血栓薬のスクリーニング方法
EP2600155A1 (de) 2012-06-18 2013-06-05 Roche Diagniostics GmbH sFlt-1-basierte Diagnose und Überwachung von Schlaganfallpatienten
EP2597467A1 (de) 2012-06-26 2013-05-29 Roche Diagniostics GmbH Mittel und Verfahren zur proSP-B-basierten Diagnose von Lungenstauung bei Patienten mit akutem Koronarsyndrom
EP2597466A1 (de) 2012-06-26 2013-05-29 Roche Diagniostics GmbH Mittel und Verfahren zur proSP-B-basierten Diagnose von Alveolenbeschädigung bei Patienten mit pulmonaler Hypertonie
WO2014009418A1 (en) 2012-07-10 2014-01-16 Roche Diagnostics Gmbh TnT, NTproBNP, sFlt-1 for CURB65 IN PNEUMONIA
CN104737170A (zh) 2012-08-21 2015-06-24 重症监护诊断股份有限公司 多标记风险分层
EP4075143A1 (de) 2012-09-12 2022-10-19 Roche Diagnostics GmbH Identifizierung von patienten mit abnormaler fraktioneller verkürzung
DK2904398T3 (en) * 2012-10-02 2018-07-23 Sphingotec Gmbh Procedures for predicting the risk of getting cancer in a female individual
US20140273273A1 (en) 2012-11-01 2014-09-18 Christie Mitchell Ballantyne Biomarkers to improve prediction of heart failure risk
EP2730923A1 (de) 2012-11-09 2014-05-14 Roche Diagniostics GmbH NTproBNP- und cTnT-basierte Therapieanleitung bei Herzversagen
WO2014072500A1 (en) 2012-11-09 2014-05-15 Roche Diagnostics Gmbh Tnt based diagnosis of paroxysmal atrial fibrillation
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
CA2893639C (en) 2012-12-04 2021-01-05 F. Hoffmann-La Roche Ag Biomarkers in the selection of therapy of heart failure
DE102012223378A1 (de) * 2012-12-17 2014-06-18 Charité - Universitätsmedizin Berlin In-vitro Verfahren und Kit zur Diagnose von akutem Koronarsyndrom
EP2937696B1 (de) * 2012-12-20 2018-06-06 National University Corporation Hokkaido University Verfahren zur erkennung von prostatabasalzellen
WO2014121252A1 (en) * 2013-02-04 2014-08-07 The General Hospital Corporation Biomarkers for stroke diagnosis
KR101494882B1 (ko) * 2013-02-21 2015-02-25 한국과학기술연구원 급성 심근 경색 진단용 조성물, 그 조성물을 포함하는 급성 심근 경색 진단용 키트 및 급성 심근 경색 진단 방법
US9020583B2 (en) 2013-03-13 2015-04-28 Siemens Medical Solutions Usa, Inc. Patient signal analysis and characterization
EP2866033A1 (de) 2013-10-23 2015-04-29 Roche Diagniostics GmbH Differenzialdiagnose von akuter Atemnot auf Basis von c-terminiertem proSP-B, KL-6 und BNP-Peptiden
US20160231334A1 (en) * 2013-10-28 2016-08-11 The Forsyth Institute Compositions and Methods for Evaluating Metabolic Syndrome and Related Diseases
WO2015063248A2 (en) 2013-11-04 2015-05-07 F. Hoffmann-La Roche Ag Biomarkers and methods for progression prediction for chronic kidney disease
CA2930790A1 (en) * 2013-11-15 2015-05-21 Christopher Joseph Pemberton Biomarker for cardiac disorders
EP3099821B1 (de) * 2014-01-27 2021-08-11 Epic Sciences, Inc. Diagnostika für zirkulierende tumorzellen zum nachweis von neuroendokrinem prostatakrebs (nepc)
EP2899544B1 (de) 2014-01-28 2018-12-26 Roche Diagnostics GmbH Biomarker zur Risikobewertung und Behandlungsüberwachung bei Patienten mit Herzinsuffizienz, die auf Basis des natriuretischen Peptids des Typs B behandelt werden
EP3108246B1 (de) 2014-02-21 2019-10-09 Epic Sciences, Inc. Verfahren zur analyse von seltenen zirkulierenden zellen
EP2916134B1 (de) 2014-03-05 2017-08-16 Roche Diagnostics GmbH Verwendung von Seprase zur Differenzialdiagnose von akuter Atemnot
ES2676553T3 (es) 2014-03-26 2018-07-20 F. Hoffmann-La Roche Ag IGFBP7 para el diagnóstico de la disfunción diastólica
AU2014407088B2 (en) 2014-09-26 2021-09-23 Somalogic Operating Co., Inc. Cardiovascular risk event prediction and uses thereof
CN113156096A (zh) 2015-01-09 2021-07-23 全球基因集团有限责任公司 用于诊断冠状动脉粥样硬化性疾病的基于血液的生物标志物
US20190064191A1 (en) 2016-02-04 2019-02-28 Metanomics Gmbh Means and methods for differentiating between heart failure and pulmonary disease in a subject
EP3440467B1 (de) * 2016-04-08 2020-05-13 Lunginnov Verfahren zur diagnose von postoperativen lungenentzündungen bei patienten nach einer operation
ES2817087T3 (es) 2016-08-04 2021-04-06 Hoffmann La Roche ESM-1 (endocan) circulante en la evaluación de la fibrilación auricular
WO2018069487A1 (en) 2016-10-14 2018-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of loss of renal function in patients with type 2 diabetes
WO2018127372A1 (en) 2016-12-13 2018-07-12 Witteman Johanna Cornelia Maria Detection of transient troponin peaks for diagnosis of subjects at high risk of cardiovascular disease
EP3360570A1 (de) 2017-02-13 2018-08-15 Roche Diagnostics GmbH Monoklonale antikörper für nt-probnp punktmutationen
CN112204397A (zh) * 2018-03-30 2021-01-08 荣研化学株式会社 新型主动脉瘤标志物
EP3572813A1 (de) * 2018-05-22 2019-11-27 Centre National de la Recherche Scientifique Diagnoseverfahren von multipler sklerose
IT201800007264A1 (it) * 2018-07-17 2020-01-17 Metodo per la diagnosi in vitro di carcinoma della prostata mediante biomarcatori urinari
CN113167799A (zh) 2018-07-31 2021-07-23 豪夫迈·罗氏有限公司 循环DKK3(Dickkopf相关蛋白3)在心房颤动评定中的应用
KR20210044216A (ko) 2018-08-10 2021-04-22 에프. 호프만-라 로슈 아게 심방세동-관련 뇌졸중 평가를 위한 ces-2 (카르복실에스테라제-2)
KR20210046675A (ko) 2018-08-16 2021-04-28 에프. 호프만-라 로슈 아게 심방 세동 및 항응고 요법의 평가에서 순환하는 tfpi-2 (조직인자경로 억제제 2)
BR112021002728A2 (pt) 2018-08-17 2021-08-10 F. Hoffmann-La Roche Ag métodos de avaliação da fibrilação atrial, de auxílio à avaliação da fibrilação atrial, de diagnóstico de insuficiência cardíaca e de predição do risco de hospitalização, método implementado por computador para a avaliação da fibrilação atrial, kit e usos in vitro
KR20210047304A (ko) 2018-08-22 2021-04-29 에프. 호프만-라 로슈 아게 심방 세동 평가에서 순환 spon-1 (스폰딘-1)
KR20210049829A (ko) 2018-08-24 2021-05-06 에프. 호프만-라 로슈 아게 심방 세동의 사정에서 및 뇌졸중의 예측을 위한 순환하는 fgfbp-1 (섬유모세포 성장 인자-결합 단백질 1)
WO2020064995A1 (en) 2018-09-28 2020-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of biomarkers representing cardiac, vascular and inflammatory pathways for the prediction of acute kidney injury in patients with type 2 diabetes
CN111192687A (zh) * 2018-11-14 2020-05-22 复旦大学附属儿科医院 一种进展期阑尾炎列线图预测模型及其用途
EP3973294A1 (de) 2019-05-23 2022-03-30 Roche Diagnostics GmbH Igfbp7-verhältnis für hfpef
US11359011B2 (en) * 2019-08-07 2022-06-14 Edifice Health, Inc. Treatment and prevention of cardiovascular disease
CN115190886A (zh) 2020-02-20 2022-10-14 马斯特里赫特大学 循环bmp10（骨形态发生蛋白10）的检测方法
CN116547537A (zh) 2020-07-29 2023-08-04 皮克托有限公司 SARS-CoV-2抗体免疫测定
CN116235056A (zh) 2020-09-30 2023-06-06 豪夫迈·罗氏有限公司 心房颤动评定中的循环总NT-proBNP(糖基化和未糖基化NT-proBNP)及其与NT-proBNP(未糖基化NT-proBNP)的比率
CN114182010B (zh) * 2022-01-11 2022-06-07 首都医科大学附属北京朝阳医院 一种血浆外泌体circRNA标志物及其应用
WO2023175152A1 (en) 2022-03-18 2023-09-21 Roche Diagnostics Gmbh Troponin marker combinations for early discrimination of type 2 versus type 1 acute myocardial infarction
WO2023175176A1 (en) 2022-03-18 2023-09-21 Roche Diagnostics Gmbh Cmybpc marker combinations for early discrimination of type 2 versus type 1 acute myocardial infarction

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5453359A (en) 1988-06-13 1995-09-26 American Biogenetic Sciences, Inc. Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers
US5206140A (en) * 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
US5422393A (en) 1988-07-11 1995-06-06 Naturon Pharmaceutical Corporation Natriuretic hormone
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
DK0479948T3 (da) 1989-06-23 1999-05-25 Genentech Inc Sammensætninger og fremgangsmåder til syntese af natriuretisk protein-receptor B og anvendelsesfremgangsmåder
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
WO1992005282A1 (en) 1990-09-14 1992-04-02 Biosite Diagnostics, Inc. Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
CA2027434C (en) * 1990-10-12 1999-01-05 George Jackowski Diagnostic kit for diagnosing and distinguishing chest pain in early onset thereof
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
WO1992018868A1 (en) 1991-04-10 1992-10-29 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
ATE195808T1 (de) 1991-04-12 2000-09-15 Biosite Diagnostics Inc Neue konjugate und testverfahren für die gleichzeitige bestimmung von multiplen liganden
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US6147688A (en) 1993-06-28 2000-11-14 Athena Design Systems, Inc. Method and apparatus for defining and selectively repeating unit image cells
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US5795725A (en) 1995-04-18 1998-08-18 Biosite Diagnostics Incorporated Methods for the assay of troponin I and T and selection of antibodies for use in immunoassays
ATE297950T1 (de) * 1996-03-04 2005-07-15 Scios Inc Testverfahren und reagenzien zur quantifizierung von hbnp
US6028055A (en) * 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US6156521A (en) 1997-12-19 2000-12-05 Biosite Diagnostics, Inc. Methods for the recovery and measurement of troponin complexes
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
EP0999447A4 (de) 1997-04-30 2002-02-27 Maruha Corp Methode zum nachweis oder zur vorhersage von ischämischen krankheiten
US6117644A (en) 1998-06-04 2000-09-12 Ottawa Heart Institute Research Corporation Predicting and detecting cardiac allograft rejection
US6171870B1 (en) 1998-08-06 2001-01-09 Spectral Diagnostics, Inc. Analytical test device and method for use in medical diagnoses
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
JP2002525102A (ja) 1998-09-29 2002-08-13 クリスチャン ベー． レーン，ラルス Ｎｃａｍ結合化合物
CA2263063C (en) 1999-02-26 2004-08-10 Skye Pharmatech Incorporated Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
AT407580B (de) 1999-08-20 2001-04-25 Biomedica Gmbh Indikatorpeptid zur diagnose und/oder vorhersage von cardiovasculären und/oder endothelialen erkrankungen, antikörperzusammensetzung und immunoassay
AUPQ893300A0 (en) 2000-07-21 2000-08-17 Newbrain Technologies Pty Limited Method and system for utilising database information
US6670138B2 (en) 2000-11-01 2003-12-30 Agy Therapeutics, Inc. Method of diagnosing ischemic stroke via UCP-2 detection
US7632647B2 (en) 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
AU2002316437A1 (en) * 2001-06-27 2003-03-03 Smithkline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors
US6627457B2 (en) 2001-07-30 2003-09-30 Quest Diagnostics Investments Incorporated Methods for detecting pregnancy
US6461828B1 (en) * 2001-09-04 2002-10-08 Syn X Pharma Conjunctive analysis of biological marker expression for diagnosing organ failure
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.

Also Published As

Publication number Publication date
EP1666881A2 (de) 2006-06-07
CA2414073A1 (en) 2002-11-14
EP1666881A3 (de) 2007-09-19
JP2004520598A (ja) 2004-07-08
EP1322957A2 (de) 2003-07-02
US20030109420A1 (en) 2003-06-12
AU2002305394A1 (en) 2002-11-18
EP1322957B1 (de) 2009-08-12
DE60233301D1 (de) 2009-09-24
EP1322957A4 (de) 2005-11-02
US7358055B2 (en) 2008-04-15
WO2002089657A3 (en) 2003-02-27
JP3806694B2 (ja) 2006-08-09
JP2006234823A (ja) 2006-09-07
EP2261669A1 (de) 2010-12-15
JP4235652B2 (ja) 2009-03-11
WO2002089657A2 (en) 2002-11-14
EP1666881B1 (de) 2010-02-17
ATE458199T1 (de) 2010-03-15
US20060063204A1 (en) 2006-03-23
ATE439588T1 (de) 2009-08-15
US7361473B2 (en) 2008-04-22
JP2005121664A (ja) 2005-05-12

Similar Documents

Publication Publication Date Title
DE60235416D1 (de) Diagnostische Marker der akuten koronaren Syndrome und ihre Verwendungen
DE602004001533D1 (de) Immunotestverfahren für Herz-Troponin I
DE69420556T2 (de) Assay für troponin i aus dem herzmuskel
ATE457459T1 (de) Homogene immunoassays für mehrere allergene
DK0539477T3 (da) Fremgangsmåde til forstærkning af emissionssignalet af en luminescerende forbindelse
WO2001057522A3 (en) Immunochromatographic methods which employ semiconductor nanocrystals
ATE402266T1 (de) Verwendung eines natriuretischen peptids vom b- typ als prognostischer indikator bei akuten koronaren syndromen
WO2007040559A3 (en) Electrochemiluminescent assay
WO2001096862A3 (en) Method for increasing luminescence assay sensitivity
CN100477959C (zh) 用于检测指纹的装置
DE50304608D1 (de) Sandwich-immunoassay zur bestimmung von proanp-teilpeptiden
PT1173770E (pt) Metodo para estimar o risco de ulcera peptica
DK1423541T3 (da) Fremgangsmåde til at bestemme multiple analytter
ATE240522T1 (de) Chemilumineszenz-immunoassay zum nachweis eines mit der chagas-erkränkung verbundenen analyts in einer probe
WO2003046140A3 (en) Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample
DE59709605D1 (de) Sensitivitätssteigerung bei der immunchemischen Bestimmung eines Analyten
DK1246945T3 (da) Fremgangsmåde til identifikation af en mærkning anbragt på et fast legeme
ATE125948T1 (de) Verwendung von zweiwertigen kationen in immunchemischen tests.
DE69601637T2 (de) Nichttrennender chemilumineszenzassay durch spezifische bindung
ATE466884T1 (de) Holo-transcobalamin bindungspartner und ihre verwendung in cobalamintest
DE68924141D1 (de) Geminale Diphenyl-Derivate und ihre Verwendung in Immunotests.
EP0363829A3 (de) Vorhersage der Sensibilität für injizierbare Radiokontrastmittel mit Hilfe eines Histamin-Freisetzungstests
ES2063732T1 (es) Equipo y ensayo para determinar un antigeno/anticuerpo en una muestra.
DK1210606T3 (da) Bruskresorptionsassays
ATE312203T1 (de) Dynamische bestimmung von analyten durch arrays auf inneren oberflächen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition